Skip to main content
Peter Kabos, MD, Oncology, Aurora, CO

PeterKabosMD

Oncology Aurora, CO

Associate Professor, Medicine, University of Colorado School of Medicine

Dr. Kabos is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
  • Connect with colleagues in the same hospital or clinic.
  • Read the latest clinical news, personalized to your specialty.

See Dr. Kabos' full profile

Already have an account?

  • Office

    12605 E 16th Ave
    Aurora, CO 80045
    Phone+1 720-848-0000

Education & Training

  • University of Colorado
    University of ColoradoFellowship, Hematology and Medical Oncology, 2006 - 2009
  • University of Southern California/Los Angeles General Medical Center (USC/LA General)
    University of Southern California/Los Angeles General Medical Center (USC/LA General)Residency, Internal Medicine, 2003 - 2006
  • Comenius University
    Comenius UniversityClass of 1998

Certifications & Licensure

  • CA State Medical License
    CA State Medical License 2005 - Present
  • CO State Medical License
    CO State Medical License 2007 - 2025
  • American Board of Internal Medicine Internal Medicine
  • American Board of Internal Medicine Medical Oncology

Awards, Honors, & Recognition

  • CMS Meaningful Use Stage 1 Certification EpicCare Ambulatory EMR, Epic Systems Corporation, 2012-2013

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • Are Oncologists Jumping the Gun with the 21-Gene Assay?
    Are Oncologists Jumping the Gun with the 21-Gene Assay?April 13th, 2017
  • Technology at UCHealth Helps Save Hair During Chemotherapy
    Technology at UCHealth Helps Save Hair During ChemotherapyAugust 31st, 2016
  • Tablets Show Promise as an Alternative to Chemotherapy in CU Cancer Center Member’s Breast Cancer Study
    Tablets Show Promise as an Alternative to Chemotherapy in CU Cancer Center Member’s Breast Cancer StudyFebruary 1st, 2024